Arrowhead Research Corp

Type: Company
Name: Arrowhead Research Corp
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Short Interest in Arrowhead Research Corp Increases By 50.2% (ARWR)

Arrowhead Research Corp (NASDAQ:ARWR) saw a large growth in short interest in the month of January. As of March 31st, there was short interest totalling 3,296,442 shares, a growth of 50.2% from the March 14th total of 2,194,857 shares, AnalystRatings.Net ... [Published American Banking News - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Jakks Among Week’s Biggest Movers

The Los Angeles Business Journal’s index of largest local public companies made gains at the end of a shortened trading week on Thursday, ahead of the markets’ close on Good Friday.The weighted LABJ Stock Index closed up 2.8 percent to 181.97 for the ... [Published Los Angeles Business Journal - Apr 18 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Very Strong Session

by Harry Boxer, www.TheTechTrader an AdviceTrade.com publication It was a big day on Wall Street today. The indices popped, pulled back twice in a 5-wave advance and ended at the session highs going away.Net on the day, the Dow was up 162.29 at 16,424.85. ... [Published Individual.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)

SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99. ... [Published Individual.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Indices Reverse Sharply to Close Higher

(AdviceTrade via COMTEX News Network) -- by Harry Boxer, www.TheTechTraderan AdviceTrade.com publicationThe stock market indices was even more volatile on Tuesday than in the last few sessions. The day started out with a little pop to the upside. They ... [Published PredictWallStreet - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Shares of Arrowhead Research Under Pressure, Down 9.2%

Written on Tue, 04/15/2014 - 12:27pmBy Nick RussoDown 9.2% to $11.34, Arrowhead Research ( NASDAQ:ARWR ), is one of today's notable movers. The Dow is down 0.4% to 16,114 and the S&P is currently down 0.4% to 1,823.Arrowhead Research is in SmarTrend's ... [Published Comtex SmarTrend - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Why Arrowhead Research (ARWR) Stock is Down Today

NEW YORK (TheStreet) -- Arrowhead Research  dipped Monday amid reports that Novartis  is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering ... [Published The Street Latest - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 1 reports

Arrowhead Research Shares Sinking Lower, Down 7.2%

One of today's notable stocks in decline is Arrowhead Research (NASDAQ:ARWR), down 7.2% to $15.70. The Dow is down 0.8% to 16,298 and the S&P is currently down 1.3% to 1,848. ... [Published Individual.com - Apr 10 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 2 reports

Why Arrowhead Research (ARWR) Stock Is Up Today

04/01/14 - 11:24 AM EDTNEW YORK ( TheStreet ) -- Arrowhead Research Corp. ( ARWR ) is up 12% to $18.41 in trading Tuesday.The jump comes following the biopharmaceutical company's announcement that it had fully enrolled and dosed the first cohort of eight ... [Published TheStreet.com - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 3 reports

Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520

PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research enrolled and dosed the first cohort of 8 patients in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus ... [Published EON Science - Apr 01 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 5 reports

Shares of Arrowhead Research Are Moving Lower on 1.4x Above-Average Volume (ARWR)

(Financial News Network On) Arrowhead Research's stock is down 5.6% to $16.40 on heavy trading volume. Approximately 2.6 million shares have changed hands today vs. average 30-day volume of 1.9 million shares. Spikes in volume can validate a breakout ... [Published Individual.com - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

Monday Sector Laggards: Biotechnology, Drugs

In trading on Monday, biotechnology shares were relative laggards, down on the day by about 5.7%. Helping drag down the group were shares of Idera Pharmaceuticals ( IDRA ), off about 24.4% and shares of Arrowhead Research ( ARWR ) down about 20.9% on ... [Published Nasdaq - Mar 24 2014]

Quotes

"There is great potential for NeoGenomics Laboratories  to grow in the future."
"We have decided to significantly reduce our internal drug discovery efforts in RNA therapeutics," Novartis told FierceBiotech in a statement. "This decision was driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow.  In the future we will have a small group working in this field and look for partnering opportunities."
...Sudhir Agrawal , D Phil., CEO of Idera, commented. "With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need. Towards this goal, our clinical development strategy for IMO-8400 is focused on B-cell lymphomas harboring the MYD88 L265P mutation, and on orphan autoimmune disease indications." The full analyst notes on Idera Pharmaceuticals Inc. are available to download free of charge at:
...ncouraging with the first dose group being enrolled and dosed in just over a week," said Christopher Anzalone, Ph D , Arrowhead's President and CEO. "According to the study protocol, we expect to begin dosing the next cohort in May and remain confident that we can release top line data in the third quarter."

More Content

All (76) | News (55) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (6)
sort by: Date | Relevance
Short Interest in Arrowhead Research Corp Incre... [Published American Banking News - Apr 18 2014]
Build Biotech Wealth on Solid Platforms: Grant ... [Published Stockboard Media Inc. - Apr 18 2014]
Jakks Among Week’s Biggest Movers [Published Los Angeles Business Journal - Apr 18 2014]
Very Strong Session [Published Individual.com - Apr 16 2014]
35.3% Return Seen to Date on SmarTrend Arrowhea... [Published Individual.com - Apr 16 2014]
Indices Reverse Sharply to Close Higher [Published PredictWallStreet - Apr 16 2014]
Shares of Arrowhead Research Under Pressure, Do... [Published Comtex SmarTrend - Apr 15 2014]
Why Arrowhead Research (ARWR) Stock is Down Today [Published The Street Latest - Apr 14 2014]
BENITEC BIOPHARMA : Chairman's Address to Share... [Published 4 Traders - Apr 14 2014]
Puma, Arrowhead Among Week’s Biggest Movers [Published Los Angeles Business Journal - Apr 12 2014]
Another Negative Day and Very Negative Week [Published TradingCharts.com - Apr 11 2014]
Arrowhead Research Shares Sinking Lower, Down 7.2% [Published Individual.com - Apr 10 2014]
Bearish Moving Average Cross by Arrowhead Resea... [Published Individual.com - Apr 10 2014]
Downtrend Call Working As Arrowhead Research St... [Published Individual.com - Apr 09 2014]
Not a Good Day for Wall Street [Published Individual.com - Apr 07 2014]
A $1 Trillion Drug Market? [Published Motley Fool - Apr 07 2014]
Patient Enrollment, Acquisitions, FDA Reviews, ... [Published ADVFN India - Apr 04 2014]
Jefferies Biotech Stocks to Buy With Breakthrou... [Published 24/7 Wall St - Apr 03 2014]
PETA Buys Stock in Pharmaceutical Firm Arrowhea... [Published PETA - Apr 02 2014]
Top Gainers under the Scanner -- Research on Tr... [Published Nasdaq - Apr 02 2014]
Top Gainers under the Scanner -- Research on Tr... [Published Financial Services - Apr 02 2014]
MNKD Breathes Easy, Arrowhead Well On Target, C... [Published RTTNews.com - Apr 02 2014]
Relatively Good Performance Detected in Shares ... [Published Comtex SmarTrend - Apr 01 2014]
Why Arrowhead Research (ARWR) Stock Is Up Today [Published TheStreet.com - Apr 01 2014]
Why Arrowhead Research (ARWR) Stock Is Up Today [Published The Street Latest - Apr 01 2014]
Arrowhead Completes Enrollment of First Cohort ... [Published Investor's Business Daily - Apr 01 2014]
Arrowhead Completes Enrollment of First Cohort ... [Published EON Science - Apr 01 2014]
Arrowhead Completes Enrollment of First Cohort ... [Published Business Wire Science: Science News - Apr 01 2014]
Arrowhead Completes Enrollment of First Cohort ... [Published Business Wire Health News - Apr 01 2014]
Global RNA Interference (RNAi) Therapy Market O... [Published Michigan Live - Apr 01 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Arrowhead Completes Enrollment of First Cohort ... [Published EON Science - Apr 01 2014]
PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research enrolled and dosed the first cohort of 8 patients in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus ...
Arrowhead Completes Enrollment of First Cohort ... [Published Business Wire Science: Science News - Apr 01 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research enrolled and dosed the first cohort of 8 patients in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus ...
Arrowhead Completes Enrollment of First Cohort ... [Published Business Wire Health News - Apr 01 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research enrolled and dosed the first cohort of 8 patients in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus ...
Arrowhead Begins Dosing in Phase 2a Trial of RN... [Published Business Wire Health News - Mar 24 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. ...
Arrowhead to Present at Barclays Global Healthc... [Published Business Wire Health News - Mar 10 2014]
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research President and CEO will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EDT at the Loews Hotel in Miami, Florida. ...
1 2 3

Press Releases

sort by: Date | Relevance
Top Gainers under the Scanner -- Research on Tr... [Published Financial Services - Apr 02 2014]
Regulatory Approvals, Pricing of Public Offerin... [Published Financial Services - Mar 10 2014]
Pre-Market Top Gainers Analysis: Smith & Wesson... [Published Financial Services - Mar 06 2014]
Critical Alerts For First Solar, Arrowhead Rese... [Published Financial Services - Jan 29 2014]
Critical Alerts For AT&T, Gold SPDR, Arrowhead ... [Published Financial Services - Jan 14 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.